Drug prices

Trump administration wants to lower seniors' insulin costs

Illustration of a syringe full of cash with some cash coming out.
Illustration: Aïda Amer/Axios

The Trump administration is working on a proposal to lower seniors' out-of-pocket costs for insulin, which have nearly doubled over the last decade.

Why it matters: Voters care deeply about prescription drug prices, and if the policy comes to fruition, it could both help seniors afford their insulin and give the administration political points.

Blues plans invest in new generic drug company

A pharmacist technician stocks drugs.
A new company will sell generic medicines at cost. Photo: George Frey/Getty Images

Eighteen Blue Cross Blue Shield insurers are investing a combined $55 million to build a new generic drug company as a subsidiary of the nonprofit Civica Rx. The firm will focus on manufacturing generics people get at the pharmacy.

Between the lines: Civica and the Blues aren't disclosing which drugs they want to make, so it's unclear how much effect this company will have. But the investment highlights the broad desire to counter generic companies that are accused of price-gouging.